Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Vaccine|February 8, 2026
A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trialTemitope Oyedele, Rachel Park, Kelly Morales, et al.Vaccine|March 5, 2026
A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-85 years of ageMatthew Davis, Craig Shapiro, Max Ciarlet, et al.Nature Communications|October 14, 2025
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19Rhiannon Edge, Sam Matthews, Bahar Ahani, et al.The Journal of Infectious Diseases|May 7, 2019
A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV InfectionLesia K Dropulic, Makinna C Oestreich, Harlan L Pietz, et al.Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.The Lancet. Infectious Diseases|February 27, 2025
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trialGhady Haidar, Steven Thomas, Paul Loubet, et al.Clinical Drug Investigation|January 16, 2026
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-studyAndrew Ustianowski, Myron J Levin, Stephane De Wit, et al.Science Translational Medicine|June 26, 2024
AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adultsYingyun Cai, Seme Diallo, Kim Rosenthal, et al.Science (New York, N.Y.)|August 10, 2013
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccineRobert A Seder, Lee-Jah Chang, Mary E Enama, et al.Nature Medicine|May 10, 2016
Protection against malaria at 1 year and immune correlates following PfSPZ vaccinationAndrew S Ishizuka, Kirsten E Lyke, Adam DeZure, et al.Pageof 2